Summary

For those scared of needles but who need GLP-1 receptor agonists to help manage their weight, there might be some good news. Researchers are testing a new oral, small-molecule GLP-1 receptor agonist called Elecoglipron, which could offer the weight-loss benefits of GLP-1 therapy without injections. To see how well it works, researchers conducted VISTA, a Phase II clinical trial across seven countries involving adults living with obesity or overweight who did not have diabetes.

AI summaries can be wrong sometimes—always verify important details using the source article.